Expand safety, efficacy & access for therapeutic biologics leveraging BioPYM  oral administration  

 

Our oral biologics for gastrointestinal (GI) disorders will:

1. Improve patient safety with no systemic toxicities

2. Improve efficacy with biologics targeted directly to GI where disease occurs

3.  Improve patient accessibility to biologics with at home, non-refrigerated, convenient oral capsules

4.  Improve patient compliance with no needles and no  health-care administrated infusion

5.  Improve chronic use outcomes given the high safety profile, no ADA, no systemic toxicity​

​​

The Fzata proprietary oral Bioengineered Probiotic Yeast Medicines (BioPYM) uses yeast micro-factories to make biologic therapeutics “on-site” in the gut for treatment of GI diseases.  

​